Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 801–900 of 1,001
Seagroves, A., Ross, H. M., Vidmar, A. P., Geffner, M. E., Kim, W. S., Hwang, D., Borzutzky, C., Fraga, N. R., & Kim, M. S. (2021) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2021.2020.0310 · Cited by 4
Pharmacological Approaches in Obesity Treatment
Erden, E. E., YAZICI, Z. G., KILIÇ, C., Aydın, S., & Kılıç, F. S. (2022) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.1093390 · Cited by 4
Impact of refitted race‐free eGFR formula on obesity pharmacotherapy options
Orandi, B. J., McLeod, C., Reed, R. D., Kumar, V., Igel, L. I., Aronne, L. J., Cannon, R. M., Lewis, C. E., & Locke, J. E. (2022) · Obesity · doi:10.1002/oby.23542 · Cited by 4
“BMI >27 kg/m(2) with the presence of at least one obesity-related complication (T2DM, hypertension, hyperlipidemia) (Figure 1) [26, 27].”
BackgroundSelf-citationZaki, A. M., Abo‐elnour, D. E., Abdalla, Y. E., Hassan, R. Y., Salama, M. K., Elboraay, T., & Abdelhaleem, I. A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102657 · Cited by 4
Patel, P. N., Fox, C. K., Bensignor, M. O., & Bomberg, E. M. (2022) · JCEM Case Reports · doi:10.1210/jcemcr/luac038 · Cited by 4
“After semaglutide was added to his AOM regimen, he experienced a further reduction in hunger and was able to better adhere to a lower calorie diet, possibly due to improved satiety [2].”
BackgroundMethodInfluentialDiBattista, J. V., Lok, A. S.-F., & Chen, V. L. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000044 · Cited by 4
Jayaprakash, M. S., Beavers, D. P., Miller, G. D., McNatt, S. S., Fernandez, A., Edwards-Hampton, S. A., & Ard, J. D. (2023) · Journal of Surgical Research · doi:10.1016/j.jss.2022.12.024 · Cited by 6
A Review on Nanotechnology Mediated - Herbal Drug Delivery for the Treatment of Obesity
Shree, D., Patra, C. N., & Sahoo, B. M. (2023) · The Natural Products Journal · doi:10.2174/2210315513666230412111914 · Cited by 5
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population*
Nadolsky, K. Z. (2018) · Military Medicine · doi:10.1093/milmed/usx074 · Cited by 4
Ando, T., Hatada, K., Sata, M., Tachiki, H., Fukazawa, T., Kusumoto, S., Horie, I., Abiru, N., Matsumoto, S., & Kawakami, A. (2018) · Acta medica Nagasakiensia · doi:10.11343/amn.61.151 · Cited by 5
“Although we did not try, it may be possible to switch to other anti-obesity reagents including topiramade and sibutramine temporarily, and then switch back to GLP-1 receptor agonists to utilize their anorectic effects maximally, as the switching of anti-obesity reagents is recommended in the guideline (29).”
BackgroundLahiri, S. W. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.115 · Cited by 4
Kiel, J. (2015) · Journal of Obesity & Weight loss Therapy · doi:10.4172/2165-7904.s5-007 · Cited by 5
“Pharmacotherapy used as an adjunct to lifestyle changes can assist with weight loss in individuals who are obese, but it is considered as a second line treatment when lifestyle intervention alone is not successful [11].”
BackgroundSánchez, A. V., García, G. M., & Narankievickz, D. (2017) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2017.10.002 · Cited by 12
Latest Developments and Future Perspectives in the Field Of Obesity
Pérez‐Pevida, B., & Miras, A. D. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.01.17 · Cited by 4
“These include lorcaserin, the combination of topiramate with phentermine and the combination of naltrexone and bupropion.(10) The combination therapies appear to be particularly effective in weight loss, but due to its mode of action, they unfortunately suffer from”
BackgroundGlucagon increases energy expenditure independently of brown adipose tissue activation in humans
Izzi‐Engbeaya, C. N., Salem, V., Atkar, R. S., Coello, C. S., Thomas, D., Comninos, A. N., Buckley, A. J., Rabiner, E. A., Gunn, R. N., Tan, T., et al. (2015) · Endocrine Abstracts · doi:10.1530/endoabs.38.oc4.5 · Cited by 4
The Behavioral Treatment of Obesity
Chao, A. M., Quigley, K. M., & Wadden, T. A. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch19 · Cited by 5
Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing
Orandi, B. J., Li, Y., Seckin, T., Bae, S., Lonze, B. E., Ren‐Fielding, C. J., Lofton, H. F., Gujral, A., Segev, D. L., & McAdams‐DeMarco, M. (2024) · Clinical Transplantation · doi:10.1111/ctr.15414 · Cited by 4
“…for outsized benefits given the high prevalence of obesogenic medications in the ESKD population identified in this study, would be to avoid or minimize the use of obesogenic medications whenever possible and substitute them with weight neutral or weight-loss inducing alternatives [16, 18].”
Cheng, Z., Liu, B., & Liu, X. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1407265 · Cited by 3
“Current management strategies for obesity include lifestyle modifications (28), anti-obesity drugs (29, 74–78), and bariatric surgery (30, 79–81).”
BackgroundMalandrino, N., Metter, E. J., Simonsick, E. M., Egan, J. M., Chia, C. W., Walston, J. D., Ferrucci, L., & Kalyani, R. R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae156 · Cited by 8
Hunter, T. M., Hankosky, E. R., Meeks, A., Liao, B., Ward, J., Huang, A., & Chinthammit, C. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.05.003 · Cited by 3
Huang, T., Liao, X., Zhang, Y., Wang, P., Li, P., Fang, J., & Shao, X. (2025) · Medicine · doi:10.1097/md.0000000000044372 · Cited by 5
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Woolf, E. K., Diktas, H. E., Acosta, A. J., Apolzan, J. W., Ard, J. D., Boyle, K. E., Gilbert, J. A., Katzmarzyk, P. T., Laurienti, P. J., Lobstein, T., et al. (2025) · Obesity · doi:10.1002/oby.70015 · Cited by 8
“Since the first guidelines in 2015 endorsing pharmacotherapy for obesity, medications approved for chronic weight management have been an essential tool in the therapeutic toolbox [96].”
Self-citationChen, X., Zhang, Y., Fu, C., Huang, M., Wei, D., Zhou, W. Z., Liu, Y., Huang, B., Rao, Y., Zhang, Y., et al. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s551806 · Cited by 6
“Our study showed that, compared with SA group, 8-week EA intervention could significantly reduce the waistline, weight, BMI, hipline and Kessler 10, with these improvements persisting throughout the 24-week observational follow-up.”
InfluentialArarat, E., Rastogi, D., & Martin, B. C. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108403 · Cited by 3
Harnessing Adipose Ferroptosis: A Promising Novel Pathway for Obesity Treatment
Zayed, M., Massoud, A., Hassan, F., Elwakeel, E., Mahmoud, Y., & Jeong, B. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00669-1 · Cited by 4
“Despite decades of research and development in pharmacological interventions [2], achieving sustainable, safe, and effective weight loss for the majority of individuals with obesity remains a challenging goal [3].”
Young, C. B., Rives, E., Gudzune, K. A., Jaeger, B. C., Simmons, C., White, B. N., Hooker, S. A., Horn, D. B., Young, D. R., Vesely, J. M., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108219 · Cited by 4
The important role of comorbidities in the management of obesity
Barenbaum, S. R., Tchang, B. G., & Aronne, L. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag012 · Cited by 5
“All guidelines for the treatment of overweight and obesity recommend initiating a calorie-reduced diet, exercise, and behavioral changes [12, 41].”
Self-citationManagement of the kidney transplant candidate with obesity
Abbasi, A. B., & Orandi, B. J. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001266 · Cited by 3
Gadelmawla, A. F., Hammad, N., Atta, K., Diaa, A., Abouzkaly, F., Soni, K., Kelkar, R., Agrawal, S. P., Ahmed, R., Jain, H., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.030 · Cited by 4
Migraine across the menopausal transition and beyond: A narrative review
Korn, T. F., & Bernstein, C. A. (2026) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70071 · Cited by 5
The Síntevi Group, García-Oropesa, E. M., Martínez-López, Y. E., Ruiz-Cejudo, S. M., Martínez‐Ezquerro, J. D., Díaz-Badillo, Á., Ramirez-Pfeiffer, C., Bustamante, A., López-Sosa, E. B., Moctezuma-Chávez, Ó. O., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.665023 · Cited by 4
Medical Weight Management: A Multidisciplinary Approach
Elhag, W., & Ansari, W. E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105475 · Cited by 3
Rondanelli, M., Gasparri, C., Rigon, C., Ferraris, C., Riva, A., Petrangolini, G., Peroni, G., Faliva, M. A., Naso, M., & Perna, S. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01297-2 · Cited by 3
“Pharmacological therapy is indicated only in case of BMI > 30 kg/m(2) or BMI > 27 kg/m(2) in the presence of comorbidities [4].”
BackgroundKim, B., Lee, Y., Lee, C., Jung, E. S., Kang, H., & Holzapfel, W. H. (2024) · Foods · doi:10.3390/foods13142227 · Cited by 4
“Obesity treatment guidelines point out that weight management should include multiple approaches at the same time, including lifestyle modifications, medication, and/or bariatric surgery [3,4].”
BackgroundFirst-Generation Anti-Obesity Medications
Barenbaum, S. R., & Aras, M. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0003 · Cited by 5
Bollinger, B., Cotter, R. J., Deng, Y., Ilagan‐Ying, Y. C., & Gupta, V. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08724-y · Cited by 3
“Prescriptions of obesogenic psychiatric medications (clozapine, risperidone, olanzapine, quetiapine, haloperidol, perphenazine, amitriptyline, dox-epin, imipramine, nortriptyline, trimipramine, mirtazapine, phenelzine, tranylcypromine, carbamazepine, gabapentin, valproate) [20] were also obtained.”
Chan, J. S. W., Lau, M. S., Rosli, S. H. M., Kamal, S. K. M., Seman, W. N. N. W., Ali, N. H., Tan, T. Y. C., Ahmad, I. F., Krishnan, P., Borhan, M. K., et al. (2025) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241310206 · Cited by 4
Endoscopic Weight Loss Options
Bi, D., & Jirapinyo, P. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.11.002 · Cited by 3
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
The Birth of Bariatric Endocrinology and the Coming of Age of Obesity Medicine
González-Campoy, J. M. (2016) · US Endocrinology · doi:10.17925/use.2016.12.01.10 · Cited by 3
Levine, J. A., Kaihara, K. A., Layden, B. T., & Wicksteed, B. L. (2016) · Islets · doi:10.1080/19382014.2016.1198457 · Cited by 3
Pérez‐Segura, P., Palacio, J., Vázquez, L., Monereo, S., Peñas, R. D. L., de Icaya, P. M., Grávalos, C., Lecube, A., Blasco, A., García‐Almeida, J. M., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1601-2 · Cited by 4
“Medication for obesity in cancer patients should follow the same guidelines as for people without a history of cancer [63].”
BackgroundSedykh, D. Y., German, A. I., Hryachkova, O. N., Кашталап, В. В., & Барбараш, О. Л. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-02-08 · Cited by 5
“To date, society has formed an idea that obesity is associated with a high risk of premature death in the general population, while the maximum number of adverse outcomes, as a rule, falls on the category of people who also have other concomitant conditions: type 2 diabetes mellitus, dyslipidemia, multifocal atheroscl…”
BackgroundSetmelanotide in obesity: a profile of its use
Kang, C. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00929-3 · Cited by 3
Gastroesophageal Reflux Disease - A Growing Concern
Chai, J. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100999 · Cited by 3
Barazesh, M., Jalili, S., Akhzari, M., Faraji, F., & Khorramdin, E. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230417111247 · Cited by 3
Non-Alcoholic Fatty Liver Disease (NAFLD) and its Recent Therapeutic Strategies
Mishra, N. K., Mishra, A., & Priyadarshini, R. (2023) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2023.00022 · Cited by 3
Obesity and Hypertension: Pathophysiology and Treatment
Hall, M. E., Omoto, A. C. M., do Carmo, J. M., da Silva, A. A., & Hall, J. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00037-2 · Cited by 6
Al-Mushaigah, B. S., Almesned, R. A., Alsolai, O. A., AlFahhad, N., & Almesned, A. A. (2023) · Cureus · doi:10.7759/cureus.50477 · Cited by 4
“However, the weight loss is sustained only for as long as the medication is used [2,8].”
BackgroundKowalczuk, M., Lipińska, J., Kopeć, I., Lipiński, Ł., Kamiński, J., Klimczak, K., Loryś, L., Narloch, M., Kasprzak, S., & Kasprzak, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.59.014 · Cited by 4
Weight Loss Outcomes in a Veterans Affairs Pharmacotherapy-based Weight Management Clinic
Ni, K., Rogowitz, E., Farahmand, A., Grau, L., Arbet, J., Cunningham, C. R., Thomas, E. A., & Saxon, D. R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae042 · Cited by 3
“…of antiobesity pharmacotherapy as an adjunct to behavioral weight management, a strategy that is supported by many professional society guidelines including the VHA/Department of Defense, Endocrine Society, American Heart Association, American College of Cardiology, and The Obesity Society [7-10].”
BackgroundAssociation between a national behavioral weight management program and real-world weight change
Hung, A., Pura, J. A., Stechuchak, K. M., Dennis, P. A., Maciejewski, M. L., Smith, V. A., Blalock, D. V., Hoerster, K. D., Raffa, S. D., & Wong, E. S. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2024.05.003 · Cited by 5
White, M. E., & Kushnir, V. M. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.003 · Cited by 4
Wang, T., Zhang, X., Fan, L., Zhao, Y., Zhang, Z., Cao, Z., Xu, Y., Lee, S., Lim, C., & Zhang, S. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1436378 · Cited by 5
Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians
Laroche, H. H., Fernández, C., Sweeney, B. R., Gillette, M. L. D., & Hampl, S. E. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0005 · Cited by 3
Harnessing the power of drug repurposing: A promising strategy for drug discovery and development
Athul, H., Shaji, S., Shabik, K., & Joseph, A. (2024) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_49_24 · Cited by 5
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen, A. S., Hajduk, A. M., Grimshaw, A. A., Fried, T. R., Jastreboff, A. M., & Lipska, K. J. (2024) · Obesity · doi:10.1002/oby.24160 · Cited by 8
Duncan, J., Stevens, P. L., Bigby, E., Floyd, C., Malina, J., Nickens, J., Lambert, A., & Kantor, T. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100188 · Cited by 4
“Accordingly, there are now multiple clinical guidelines recommending various anti-obesity medications for those with BMI ≥ 30 or with a BMI ≥ 27 with a relevant weight-related comorbidity [4].”
Topiramate Extended-Release Options: A Focus on Efficacy and Safety in Epilepsy and Comorbidities
Wang, Y., Wagner, M., Kaufman, K. R., Maletsky, K. D., Sivaraaman, K., & Mani, R. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17694604 · Cited by 4
The place of central-acting drugs in the algorithms of treatment of primary obesity
Logvinova, O., Galieva, M. O., Mazurina, N. V., & Troshina, E. A. (2017) · Obesity and metabolism · doi:10.14341/omet2017218-23 · Cited by 3
Bailey, K., Easterbrook, B., Blinder, H., Hoogenes, J., & Morrison, K. M. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxy068 · Cited by 3
Garcia-Alonso, D., Morgenstern‐Kaplan, D., Cohen-Welch, A., Lozano‐Cuenca, J., & López‐Canales, J. S. (2019) · Medical Sciences · doi:10.3390/medsci7030039 · Cited by 4
“Indeed, the clinical guidelines of the Endocrine Society recommend the inclusion of diet and exercise in all regimens focused on weight loss, as well as pharmacotherapy for patients with a body mass index (BMI) ≥27 in case of presenting any comorbidity, and all of those with a BMI > 30 [3].”
BackgroundA review on the current drugs and new targets for obesity
Poojashree, M. J. (2020) · Journal of Applied Pharmaceutical Research · doi:10.18231/j.joapr.2019.v.8.i.1.002 · Cited by 3
“It was the first combination drug approved by FDA in 2012 for the longer treatment of obesity.”
MethodInfluentialCurrent Evidence-Based Treatment of Obesity
Ingersoll, A. B. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.011 · Cited by 4
Rachabattula, H., Simmons, E., Ghatahora, S., & Grant, P. S. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.059 · Cited by 3
Historical Drug Therapies in Obesity
Bashir, A., & Weaver, J. U. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00025-7 · Cited by 3
Obesity Treatment: A Focus on Pharmacotherapy of Weight Management
Patel, K. (2020) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000643 · Cited by 5
Choxi, R., Roy, S., Stamatouli, A. M., Mayer, S., & Jovin, I. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1756778 · Cited by 3
“Insulin resistance is multifactorial in origin, most commonly in a setting of obesity due to the central accumulation of adipose tissue, especially at the level of the liver, leading to unsuppressed gluconeogenesis, as well as frequently iatrogenically through the prescription of obesogenic agents [5,6].”
BackgroundCardiometabolic risk reduction after metabolic surgery
Pareek, M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000683 · Cited by 4
Blüher, M., & Stümvoll, M. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_1 · Cited by 3
Current and Emerging Pharmacotherapies for Type 2 Diabetes
Lau, D. C. W. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.095 · Cited by 3
Giusti, E. M., Spatola, C. A. M., Brunani, A., Kumbhare, D., Oral, A., Ilieva, E., Kiekens, C., Pietrabissa, G., Manzoni, G. M., Imamura, M., et al. (2020) · The Journal of the International Society of Physical and Rehabilitation Medicine · doi:10.4103/jisprm.jisprm_6_20 · Cited by 2
CORRELAÇÃO ENTRE OBESIDADE E SÍNDROME METABÓLICA: UMA REVISÃO SOBRE SEUS IMPACTOS NA SAÚDE
Carvalho, L. D. L., Pereira, R. F., Neto, S., Xavier, A. D. N., & Filho, E. G. L. (2025) · Revista Contemporânea · doi:10.56083/rcv5n4-007 · Cited by 2
Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity
Fitch, A. (2025) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2025.100621 · Cited by 3
European survey on metabolic and cardiovascular risk in Cushing syndrome
Mondin, A., Barbot, M., Ceccato, F., Pereira, A. M., Angelousi, A. G., Elenkova, A. P., Žilaitienė, B., Schalin‐Jäntti, C., Herdt, C. D., Kanaka‐Gantenbein, C., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02663-9 · Cited by 3
“Based on this statement, an ideal approach would be the one reported in Tables 3, 4 [11– 17 ].”
Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review
Afshari, S., Khosravi, M., Zamandi, M., Rezapour, A., Hadian, M., Souresrafil, A., Mazaheri, E., & Gallehzan, N. A. (2025) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_368_24 · Cited by 5
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Self-citationObesity and GEP-NEN: what’s new?
Boschetti, M., Hasballa, I., Patelli, I., Piras, G., & Albertelli, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.006 · Cited by 3
Wang, Y., Li, Y., Lin, T., & Guo, Y. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02563-z · Cited by 3
“Glucagon-likepeptide-1receptoragonists(GLP-1RAs)areincreasingly usedforobesityandtype2diabetesbecauseoftheirestablishedeffects onweightandglycemiccontrol 71 .”
Kjellberg, J., & Tikkanen, C. K. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1908130 · Cited by 2
Effectiveness and safety of herbal medicine on children with simple obesity
Shim, S. B., Lee, H. H., Ahn, H. L., Lee, J. A., & Lee, H. L. (2021) · Medicine Case Reports and Study Protocols · doi:10.1097/md9.0000000000000132 · Cited by 2
Integrating semaglutide into obesity management – a primary care perspective
Kyrillos, J. V., SKOLNIK, N., Mukhopadhyay, B., & Pennings, N. J. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2149964 · Cited by 4
“If ≥5% weight loss has been achieved within 3 months and there have been no tolerability issues, the medication can be continued [69].”
Diagnosis and Management of Obesity: A Joint Statement by Practicing Endocrinologists
Barake, M., Echtay, A. S., Hirbli, K., Saab, C., Medlej, R., & Atallah, P. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.132008 · Cited by 2
Childhood obesity: An approach to individualized treatment
Collins, P. B., & Brolis, N. V. (2022) · Osteopathic Family Physician · doi:10.33181/13066 · Cited by 2
Livzan, M. A., Lyalyukova, E. A., Друк, И. В., Safronova, S. S., Аскерович, Х. А., Martirosian, K. A., Petrosian, V. Y., & Galakhov, Y. S. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-218-10-5-47 · Cited by 4
Herbal Treatments for Obesity: A Review
Gasmi, A., Noor, S., Mujawdiya, P. K., Akram, M., Manzoor, A., & Bjørklund, G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673287491240315055726 · Cited by 4
Pastor, P. L., Amin, A., Galvan, D. L., Vasquez, O. N., Almandoz, J. P., & Lingvay, I. (2024) · Obesity Science & Practice · doi:10.1002/osp4.755 · Cited by 2
“16 Despite increase number of approved anti ‐ obesity medications (AOMs) (phentermine, phentermine ‐ topiramate, orlistat, bupropion ‐ naltrexone, liraglutide 17 and semaglutide 18 ), all are underutilized in this population due to concerns related to their effectiveness and tolerability.”
BackgroundAn Overview of Modern Strategies for Treating Obesity
Jędrasek, A., Barg, M., Biały-Karbowniczek, J., Bartela, A., & Wojtyła, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.68.49506 · Cited by 2
The risks and benefits of managing obesity in older adults
Carroll, D. G. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae288 · Cited by 2
Yskout, M., Steenackers, N., Hoste, J., Pazmiño, S., Simoens, C., Mattelaer, N., Deleus, E., Lannoo, M., Mertens, A. C., der Schueren, B. V., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01870-x · Cited by 5
“The low incidence of diabetes mellitus is consistent with clinical guidelines, as patients with type 2 diabetes are preferably offered a GLP-1 analogue to target body weight reduction in combination with glycaemic control [28].”
Mi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
“Pharmacological therapy is also recommended for patients with BMI 27––30 kg/m 2 or ≥ 30 kg/ m 2 BMI with more than one obesity-related complication [5].”
An obesity care curriculum improves residents’ self-efficacy and clinical practice habits
Laudenslager, M., Chae, K., Tackett, S. A., Bertram, A. K., & Gudzune, K. A. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100223 · Cited by 2
Obesity: a global health problem
Jha, A. K., & Das, A. K. (2019) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20192870 · Cited by 2
Anderson, M. R., Aronson, K. I., Diamond, J. M., Christie, J. D., & Singer, J. P. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202201-019rl · Cited by 2
Naltrexone ER/bupropion ER in obesity management: a guide to its use
Greig, S. L., & Keating, G. M. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0253-6 · Cited by 2
“A reduced-calorie diet, increased physical activity and behavioural modification are recommended as the basis of any bodyweight management strategy [1, 3]; however, in many overweight or”
BackgroundInvesting in Obesity Treatment: Kaiser Permanente’s Approach to Chronic Disease Management
Tsai, A. G., Histon, T., Donahoo, W. T., Hashmi, S., Murali, S. B., Latare, P., Oliver, L., Slovis, J., Grall, S. K., Fisher, D. P., et al. (2016) · Current Obesity Reports · doi:10.1007/s13679-016-0223-x · Cited by 5
Intragastric balloons for weight loss: Not just occupying space in the stomach
Sullivan, S. A., & Edmundowicz, S. A. (2016) · Obesity · doi:10.1002/oby.21604 · Cited by 2
“The results of this study may also help to explain the weight maintenance that is seen in the first 6 months after intragastric balloon removal (7) and is in contrast to the weight gain that is seen immediately after cessation of obesity medications (8).”
ResultHandelsman, Y., Fain, R., Wang, Z., Li, X., Fujioka, K., & Shanahan, W. R. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1240591 · Cited by 2
“Although diet and exercise are the cornerstones of any weight-reduction recommendation, weight loss through exercise and caloric restriction alone may be hampered by several factors [4].”
BackgroundPalmer, K. D., & Apovian, C. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00022-9 · Cited by 2
Self-citationTratamiento médico-quirúrgico de la obesidad en el SAHOS
Escobar, I. D., Muñoz-Mora, A., & Palacio, N. L. (2017) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v65n1sup.60090 · Cited by 2
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.